Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Lancet Gastroenterol Hepatol. 2020 May;5(5):494-506. doi: 10.1016/S2468-1253(19)30326-7.
Alcoholic hepatitis is an acute, inflammatory liver disease associated with high morbidity and mortality both in the short term and long term. Alcoholic hepatitis often arises in patients with a background of chronic liver disease and it is characterised by the rapid onset of jaundice and the development of myriad complications. Medical therapy for severe alcoholic hepatitis relies on corticosteroids, which have modest effectiveness. Abstinence from alcohol is critically important in patients with alcoholic hepatitis, but recidivism is high. Because of the absence of effective medical treatments for alcoholic hepatitis and alcohol dependency, there is a pressing need to develop new and effective therapeutics. Supported by promising preliminary and preclinical studies, many ongoing clinical trials of new therapies for alcoholic hepatitis are currently underway and are discussed further in this Series paper.
酒精性肝炎是一种急性炎症性肝病,无论是短期还是长期,其发病率和死亡率都很高。酒精性肝炎常发生于慢性肝病患者,其特征为黄疸迅速出现,并伴有多种并发症。严重酒精性肝炎的医学治疗依赖于皮质类固醇,其疗效有限。酒精性肝炎患者必须严格戒酒,但复发率很高。由于缺乏治疗酒精性肝炎和酒精依赖的有效药物,因此迫切需要开发新的有效治疗方法。有了有希望的初步和临床前研究的支持,目前正在进行许多针对酒精性肝炎新疗法的临床试验,本综述进一步讨论了这些临床试验。